Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055881 · ClinicalTrials.gov registry record · NA
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
A NA study of Metastatic Breast Cancer and Breast Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT06055881 is a NA study of Metastatic Breast Cancer and Breast Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06055881, a NA study of Metastatic Breast Cancer and Breast Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
- OTHER Surveys
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2032-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06055881
The ClinicalTrials.gov registry entry for NCT06055881 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06055881 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06055881 about?
NCT06055881 is a clinical study titled "Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy". This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease
What is the current status of trial NCT06055881?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2023-10-23. Estimated completion is 2032-05-01.
What conditions does trial NCT06055881 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8.
What interventions are being tested in trial NCT06055881?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Stereotactic Body Radiation Therapy (SBRT) (RADIATION), Surveys (OTHER).
Who is sponsoring clinical trial NCT06055881?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055881 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Adaptation of a Values Assessment Tool
RECRUITING · NA
-
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
RECRUITING · NA
-
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
RECRUITING · NA
-
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
RECRUITING · NA
-
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.